New features of glatiramer acetate for the treatment of remitting multiple sclerosis

Abstract

The article discusses usage of the new dosage of glatiramer acetate (Copaxone®) for the treatment of relapsing-remitting multiple sclerosis. Results of phase II and III clinical trials are presented. Randomized clinical trials GALA and GLACIER demonstrated high efficacy, good safety and tolerability of glatiramer acetate taken in dosage 40mg/ml 3 times per week.

Keywords

• рассеянный склероз
• препараты
• изменяющие течение рассеянного склероза (питрс)
• глатирамера ацетат
• multiple sclerosis
• multiple sclerosis disease-modifying medications (msdmm)
• glatiramer acetate